Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA '522' Guidance: 15-Month Deadline To Comply With Postmarket Order

This article was originally published in The Gray Sheet

Executive Summary

The agency has issued a final guidance on Sec. 522 postmarket study orders about five years after a draft version. In the interim, Congress stipulated a 15-month deadline for companies to start the FDA-mandated studies, a requirement emphasized in the new document.


Related Content

In Case You Missed It: Top 10 Gray Sheet Stories In May
Senate Seeks Performance Data From FDA On De Novos, Postmarket Surveillance
Warning Letter: Exoskeleton Firm Dodged Communication With FDA Over Postmarket Study, Failed To Assemble Surveillance Plan
Duodenoscope-Makers Ordered By FDA To Conduct Sec. 522 Postmarket Surveillance Studies
Metal-On-Metal Hip Post-market Studies Behind Schedule, NEJM Article Highlights
FDA Emphasizes Efficiency In 522 Surveillance Order Draft Guidance


Related Companies